SciSparc Ltd. has signed a binding term sheet to acquire the full portfolio of patents, trademarks, know-how, and related intellectual property rights, primarily associated with the MUSE™ system, from Xylo Technologies Ltd. The MUSE™ system is a single-use endoscopic device designed for transoral fundoplication, a minimally invasive treatment for gastroesophageal reflux disease (GERD). Under the agreement, SciSparc will issue to Xylo ordinary shares representing 19.99% of SciSparc's issued and outstanding share capital at closing, with the option to issue pre-funded warrants instead. Building on Xylo's prior commercialization success in Greater China, SciSparc plans to pursue similar partnerships to expand into markets in North America, Europe, and Latin America.